Premium
Plasma cell depletion with bortezomib in the treatment of refractory N ‐methyl‐ d ‐aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment
Author(s) -
Keddie S.,
Crisp S. J.,
Blackaby J.,
Cox A.,
Coles A.,
Hart M.,
Church A. J.,
Vincent A.,
Zandi M.,
Lunn M. P.
Publication year - 2018
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.13759
Subject(s) - bortezomib , medicine , rituximab , antibody , plasma cell , immunology , refractory (planetary science) , pharmacology , pharmacodynamics , encephalitis , multiple myeloma , biology , pharmacokinetics , virus , astrobiology
Background and purpose The aim was to assess the therapeutic potential of bortezomib in the treatment of refractory N ‐methyl‐ d ‐aspartate receptor ( NMDAR ) antibody encephalitis and its potential in other immune‐mediated, B‐cell‐driven neurological diseases. Methods Two cases of severe NMDAR antibody encephalitis, resistant to first and second line therapy with steroids, intravenous immunoglobulins, plasma exchange, cyclophosphamide and rituximab, were treated with four and five cycles of 1.3 mg/m 2 bortezomib at 350 and 330 days following initial presentation. Results Both patients showed significant clinical improvement with reductions of NMDAR antibody titres following bortezomib treatment. This is the first case in the literature where the NMDAR antibody level was undetectable following treatment with bortezomib. Conclusion Bortezomib's unique ability to target long‐lived autoreactive plasma cells appears to be a useful adjunct to standard second line immunosuppressive therapy in treatment‐refractory NMDAR antibody encephalitis. The drug's pharmacodynamics, cell targeting and mechanism of action are reviewed, and it is postulated that bortezomib may be useful in a host of B‐cell‐driven neuroimmunological diseases.